New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
10:47 EDTINCYIncyte announces results from RESPONSE trial evaluating ruxolitinib
Incyte announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera. Ruxolitinib, compared to best available therapy (BAT), significantly improved hematocrit control without the need for phlebotomy and reduced spleen size in patients with uncontrolled PV. Findings from the RESPONSE study are being presented in an oral presentation at the 50th Annual Meeting of the American Society of Clinical Oncology. At a median follow-up of 81 weeks, 85% of patients in the ruxolitinib arm were still receiving treatment. Because most patients in the BAT group crossed over to receive ruxolitinib therapy at week 32, adverse events were evaluated at this time when exposure between groups was similar. The most common non-hematologic adverse events of any grade in the ruxolitinib group compared to the BAT group were headache, diarrhea, fatigue and pruritus. The company said, “One out of four patients with polycythemia vera remain uncontrolled, face a profound symptom burden and are at greater risk of cardiovascular complications such as stroke and heart attack. These Phase III data give us confidence that ruxolitinib has the potential to become an important new treatment option for patients with uncontrolled PV who are no longer responding to or are intolerant of hydroxyurea.”
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
07:31 EDTINCYIncyte appoints Steven Stein as Chief Medical Officer
Subscribe for More Information
February 26, 2015
07:37 EDTINCYIncyte to sponsor U.S. polycythemia vera study
Incyte announced that it is sponsoring the first major observational study of patients living with polycythemia vera in the U.S. PV is a rare and progressive blood cancer that can lead to debilitating symptoms, serious cardiovascular complications, and death.The REVEAL study will seek to describe the real-world clinical burden of PV and how healthcare services are utilized in the management of this disease. Incyte is partnering with approximately 200 community and academic medical centers to conduct the study in the U.S. REVEAL, which recently began enrolling patients, is expected to include 2,000 patients under the supervision of a physician for the active management of PV for a period of three years.
February 23, 2015
07:30 EDTINCYIncyte price target raised to $89 from $75 at Oppenheimer
Oppenheimer increased its price target on Incyte after the company reported that sales of its flagship Jakafi drug had jumped 46% year-over-year in Q4. The firm continues to be upbeat on Jakafi's revenue outlook and the company's pipeline. It keeps an Outperform rating on the shares.
07:06 EDTINCYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use